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Biased signaling is a concept that has arisen in the G protein-coupled receptor (GCPR)
research field, and holds promise for the development of new drug development strategies. It
consists of different signaling outputs depending on the agonist’s chemical structure. Here
we review the most accepted mechanisms for explaining biased agonism, namely the
induced fit hypothesis and the key/lock hypothesis, but we also consider how bias can be
produced by a given agonist. In fact, different signaling outputs may originate at a given
receptor when activated by, for instance, the endogenous agonist. We take advantage of
results obtained with adenosine receptors to explain how such mechanism of functional
selectivity depends on the context, being receptor-receptor interactions (heteromerization)
one of the most relevant and most studied mechanisms for mammalian homeostasis.
Considering all the possible mechanisms underlying functional selectivity is essential to
optimize the selection of biased agonists in the design of drugs targeting GPCRs.
Keywords: cAMP, MAPK pathway, adenylyl cyclase, GPCR, tetramer, heteromer, receptor-receptor interactions,
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INTRODUCTION
Biased signaling consists of different signaling outputs depending on the agonist chemical structure.
The concept has taken hold in the field of G protein-coupled receptor (GPCR) research and has
opened up new perspectives for therapeutic drug development. The underlying idea is that a given
agonist biased towards a particular signaling may be therapeutic while another agonist biased
towards activating an alternative pathway may not be helpful, and may even be harmful.
Biased agonism is an attractive concept to try to get agonist use off the ground in clinical
practice. At present, agonists have by far less potential than antagonists. Usually, endogenous
agonists approved as therapeutic drugs are used in acute conditions and during short times. In
contrast, antagonists may be used in a chronic regime. The classical example is epinephrine that is
used as adrenergic agonist to save lives in critical situations (e.g., anaphylaxis) whereas beta-
adrenergic blockers/antagonists are used for a variety of diseases in both acute and chronic
regimes. In the purine field, adenosine is used in bolus administration to combat paroxysmal
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tachycardia whereas the adenosine A2AR antagonist,
istradefylline (Nouriast™ in Japan; Nourianz™ in the
United States), has been approved for chronic use in the
therapy of Parkinson’s disease (Pinna et al., 2007; Simola
et al., 2008; Jenner et al., 2009; Mizuno and Kondo, 2013;
Kondo et al., 2015; Navarro et al., 2015).
Two complementary points of view are needed to underline
the mechanisms underlying differential signaling arising from a
given GPCR. In a previous paper we already made a distinction
between biased signaling and biased functionality (Franco et al.,
2018). Here we will provide more information on the possibility
that biased signaling arises from different compounds acting on
the same receptor but, also, on the possibility that biased
signaling arises from the same agonist acting in the same
receptor but expressed in a different context. By different
context we mean that a given GPCR may be expressed in
different cells coupled to different proteins, not only to
different G proteins but to other receptors, to scaffolding
proteins, etc.
THE MOST ACCEPTED MECHANISM TO
EXPLAIN BIASED SIGNALING
The resolution of the structure of various GPCRs and the
molecular dynamics of macromolecules in aqueous solutions
give indications as to how GPCR-mediated signaling occurs.
Binding of the agonist to the orthosteric site leads to
significant structural rearrangements that are transmitted to
the coupled G protein and allow signaling (Westfield et al.,
2011; Masureel et al., 2018).
It is not necessary to be very specific with the details to explain
the basis of the most accepted mechanism underlying biased
signaling. In fact, assuming that GPCRs have a loose orthosteric
center, the binding of structurally different chemicals to the site
can result in different conformations (Figure 1 up). Said different
conformations will couple differently to the signaling machinery,
thus providing different signaling outputs. The agonist/receptor
interaction would be similar to the so-called induced fit in the
case of a substrate that interacts with the active site of an enzyme
FIGURE 1 | Three ways to deliver biased signaling. Top: G protein coupled receptor (GPCR) orthosteric center of the GPCR has a loose conformation that is fixed
upon agonist binding, thus allowing coupling and engagement of the signal transduction machinery (STM). Center: There are different conformational states of a given
GPCR with structurally different orthosteric sites; each agonist preferentially binds to a given conformation thus preferentially engaging a given STM. Bottom: A given
ligand acting on a given GPCRmay lead to different signaling outputs depending on the context of the receptor. The case of heteromer formation is exemplified with
a given adenosine receptor (AR) able to interact with GPCRA or with GPCRB.
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(Urban et al., 2007; Kenakin and Miller, 2010) (Kenakin, 2009;
Kenakin, 2011; Kenakin and Christopoulos, 2013).
Following the analogy with substrate/enzyme interaction,
there is another point of view which is that the cell surface
receptor is in different conformational states while waiting for the
arrival of the agonist. Similar to the key/lock idea (Figure 1
center), each of these conformational states would have a
different lock and each agonist would interact more strongly
(i.e., with more affinity) with some conformations than with
others (Costa-Neto et al., 2016; Michel and Charlton, 2018).
In summary, in the classical view each agonist favors a specific
signal transduction and that this may be due to two conceptually
different mechanisms. One is by assuming different receptor
states due to pre-coupling to signaling mechanisms and each
chemical structure preferentially binding to a given state, thereby
preferentially engaging such particular signaling pathway. The
second is by assuming the GPCR in a given state that, after
agonist-induced conformational changes, would lead to a
receptor prone to interact to (and engage) a particular
signaling machinery.
THE ALTERNATIVE MECHANISM TO
APPROACH BIASED SIGNALING. HOW THE
ENDOGENOUS AGONIST MAY PROVIDE
FUNCTIONAL DIVERSITY
Biased agonism fits into a more general framework, called
functional selectivity. A given GPCR may provide different
signaling outputs depending on the context. In other words,
functional selectivity may be afforded using a single agonist.
Yet another way to express the idea is that the endogenous
agonist (hormone/neurotransmitter) will give rise to different
signals depending on the cell/tissue and the general
pathophysiological state.
We argue, as suggested elsewhere (Franco et al., 2018), that
biased signaling does not require a biased agonist, that is, that the
endogenous agonist may engage different signaling pathways
depending on the cell context. In short, it would be the
functional unit itself, made up of the receptor and the direct
receptor/receptor and receptor/protein interactions, which is
coupled to a certain signaling machinery. Consequently, cells
will respond according to the coupling assigned to the specific
structure of the functional unit and the existence, or not, of more
than one functional unit.
Below we will present some examples of differential functional
selectivity provided by an endogenous agonist (Figure 1 bottom).
Let us first describe the classic case discovered by Susan George
and her colleagues working with dopamine receptors. According
to IUPHAR, the cognate G proteins for the D1 and D2 receptors
are, respectively, Gs and Gi (Alexander et al., 2019). However, D1
and D2 can interact to form D1-D2 receptor heteromers that do
not couple to Gs/Gi but to Gq. Coupling to Gq allows dopamine to
activate not only cAMP- but also calcium-related mechanisms
(Lee et al., 2004; Rashid et al., 2007; Perreault et al., 2015;
Perreault et al., 2016). The controversy that arose about the
appearance of such complexes in primates has been resolved
by finding that about 18% of the neurons of the striatum of
Macaca fascicularis express the D1-D2 receptor heteromers (Rico
et al., 2016). In fact, there are neurons in different parts of the
central nervous system that expressing those heteromers provide
a long-suspected link between dopaminergic neurotransmission
and calcium signals.
Dopamine D1 receptors can also form heteromers with
histamine receptors, whose exact role in the central nervous
system has yet to be fully clarified. Interestingly, the formation
of D1 and the histamine H3 receptor heteromer is required for
histamine to activate the mitogen-activated protein kinase
(MAPK) signaling pathway. Surprisingly, it appears that D1
receptors within this heteromeric context bind to Gi rather
than its cognate G protein, Gs. (Ferrada et al., 2009).
A final example we provide here is related to GPCRs that
regulate intraocular pressure. Melatonin receptors form
functional complexes with α1-adrenergic receptors, which
involve the C-terminal tail of the latter. Surprisingly, activation
of α1-adrenergic receptors in this particular heteromeric context
does not lead to changes in cytoplasmic levels of Ca2+ but of
cAMP. Once again, the heteromeric context leads to a change,
from Gq to Gs, in the G protein coupling (see Figure 1 bottom).
Glaucoma coursing with elevated intraocular pressure is
correlated with a decreased expression of the complexes in
stromal cells (Alkozi et al., 2019; Alkozi et al., 2020). Whether
this fact is a cause or a consequence of the disease, the melatonin-
adrenergic heteromers arise as targets for fighting the disease.
BIASED SIGNALING UNDER THE PRISMOF
RESULTS DERIVED FROM ADENOSINE
RECEPTOR SIGNALING
CHARACTERIZATION
Four are the adenosine receptors identified so far in mammals:
A1, A2A, A2B, and A3. The cognate G proteins for the A1 and the
A3 are of the Gi type and the cognate G proteins for the A2A and
the A2B are of the Gs type. Via G protein-mediated signaling or via
the ßγ subunits of G proteins, activation of adenosine receptors
may activate the mitogen-activated protein kinase (MAPK)
pathway. Also ß-arrestin recruitment may lead to receptor
internalization and intracellular signaling (see Borea et al.,
2018 for review).
Recently, we have performed a classic study of biased agonism
using one of the four adenosine receptors, the A2A, expressed in a
heterologous system. In addition to identifying two chemical
structures, PSB-0777 and LUF-5834, that behaved differently
from the rest of the agonists, we noticed that removing part of
the receptor’s C-terminal tail does not qualitatively change the
results (Navarro et al., 2020). This finding was unexpected as the
long C-terminal end of the receptor is potentially interacting with
some components of the signaling machinery. Interestingly,
removal of the C-terminal tail of the A3 receptor is
dispensable for its capability to recruit ß-arrestins (Storme
et al., 2018).
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It is now suspected that the four adenosine receptors, A1, A2A,
A2B, and A3, can interact with each other. The A1-A2A, A1-A3, and
A2A-A2B interactions have already been described (Ciruela et al.,
2006a; Hill et al., 2014; Hinz et al., 2018; Lillo et al., 2020). The
interaction between the adenosine A2A and A1 receptors was
identified several years ago (Ciruela et al., 2006a) and the
functional role of the complex has been well understood ever
since (Ciruela et al., 2006b; Cristóvão-Ferreira et al., 2013; Lin
et al., 2020). A recent review on structure and function of
adenosine receptor heteromers is available (Franco et al., 2021).
Adenosine leads to marked biased signaling based on the
heteromeric context, even considering only interactions
between adenosine receptors. On the one hand, signaling
mediated by the A3 receptor is blocked if A2AR is co-
expressed and A2A-A3 receptor heteromers are formed. A2A
receptor antagonists abrogate the blockade, thus providing a
novel approach to the development of drugs that target the
heteromers of the A2A-A3 receptor. On the other hand, the
expression of the A2B receptor blocks signaling through the
A2A receptor. This finding raises several questions, as the A2A
receptor has a much higher affinity for adenosine than the A2B.
The actual physiological significance of this interaction is under
close scrutiny, although the A2A-A2B receptor functional complex
has already been shown to be relevant in aging and obesity (Gnad
et al., 2020).
Remarkably, the A1-A2A receptor heteromer adds an
additional dimension to functional selectivity. In fact, the
signal is biased not only by the endogenous agonist, but also
by its concentration. As we often mention, this complex is an
adenosine concentration sensor. At concentrations at which only
the A1 receptor is occupied by adenosine, only Gi-mediated
signaling is observed, with Gi being the cognate protein of the
A1 receptor. In contrast, when the adenosine concentration
increases and the A2A receptor is occupied, only Gs-mediated
signaling originates in the heteromer, with Gs being the cognate
protein of the A2A receptor. The mechanistic molecular basis of
such a phenomenon has been fully elucidated and, more
importantly, it is the C-terminal tail of A2A that is relevant for
blocking the partner (A1) receptor function (Navarro et al., 2016;
Navarro et al., 2018).
In summary, biased signaling is produced by the endogenous
agonist, adenosine, depending on the context of the target
receptor, even depending on the adenosine concentration
itself. It should be noted that the panorama of functional
diversity that adenosine can cause is not limited to the
interaction between adenosine receptors, but extends to the
complexes that adenosine receptors establishes with other
GPCRs or other proteins (see (Ginés et al., 2001; Agnati
et al., 2003; Burgueño et al., 2003; Franco et al., 2005;
Ciruela et al., 2006b; Fuxe et al., 2007; Navarro et al., 2014)
for review).
CONCLUSION
The hopes placed on the biased agonism to give an extra boost
to the drug discovery are not being fulfilled. For the above
reasons, a biased agonist may provide a benefit in a given setting
but provide a detrimental effect in other receptor settings and
thus not be useful in therapy. Also relevant is how to reliably
measure the output of the signaling pathway one wants to
target; in fact, different assays claiming to evaluate the same
pathway may produce a different result, some suggesting bias,
some not. One wonders if it would be more proactive to skip
in vitro pharmacological assays and test different agonists for
their efficacy and safety in in vivo disease models. To date,
trying to decipher the mechanism underlying functional
selectivity for a given GPCR is challenging. Without this
information, it is virtually impossible to optimize the
selection of biased agonists for drug development. Therefore,
it seems necessary to carry out an investigation aimed at
knowing both 1) what is the signaling pathway to target 2)
how to reliably measure the pathway output and 3) what is the
status of the target GPCR. Status means identifying the
proteins/receptors that interact with the target GPCR and
how that macromolecular complex is specifically coupled to
the signaling machineries.
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